Prevalence of sensorineural hearing loss in patients with head and neck malignancy who underwent chemotherapy and or radiotherapy

Anu Jacob, Erin Jino M., Gopakumar K. P., Chethan Kumar, Kiren T.


Background: Our study aimed to focus on the importance of the rate at which the sensory neural hearing loss (SNHL) is caused by chemotherapy (CT) and or radiotherapy (RT). This study also tells about the importance of informing the patient and the caretakers prior to the start of treatment for carcinoma, so that they can be prepared for it if it happens.  

Methods: Total 75 patients who were diagnosed to have any form of head and neck malignancy formed the study group. Pure tone audiometry was recorded pre-treatment, one month after treatment and six months after treatment. All the data obtained were bio statistically analysed by running in SPSS software version 26.   

Results: There is a correlation between CT, RT and concurrent chemo radiotherapy (CRT) and SNHL. It is also found that most of the patients who have undergone CRT suffered SNHL in the long run.  

Conclusions: It is high time the patients are made aware of the side effects like SNHL before the start of the proposed treatment. This will allow them to be prepared and then face it.  



Head and neck malignancy, Sensory neural hearing loss, Chemotherapy, Radiotherapy, Concurrent chemo radiotherapy

Full Text:



Sankaranarayanan R, Masuyer E, Swaminathan R, et al. Head and neck cancer: A global perspective on epidemiology and prognosis. Anticancer Res. 1998;18:4779–86

Robbins KT, Storniolo AM, Kerber C, et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 1994;12:2113–20.

Robbins KT, Vicario D, Seagren S, et al. A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg. 1994;168:419–22.

Madasu R, Ruckenstein MJ, Leake F, et al. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 1997;123:978–81.

Schell M, McHaney VA, Green AA. Hearing loss in children and young adults receiving cisplatin with and without prior cranial irradiation. J Clin Oncol 1989;7:754-760.

Pignon JP, Bourhis J, Domenge C. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet. 2000;355:949-55.

Markman M, D’Acquisito R, Iannotti N, et al: Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate. J Cancer Res Clin Oncol 1991;117:151-5.

Theunissen EA, Bosma SC, Zuur CL, Spijker R, van der Baan S, Dreschler WA, et al. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head and Neck 2013.

Low WK, Toh ST, Wee J, Fook-chong SMC, Wang DY. Sensorineural Hearing Loss After Radiotherapy and Chemoradiotherapy : A Single , Blinded , Randomized Study. J Clin Oncol. 2006;24(2015):1904–9.

Chan SH, Ng WT, Kam KL, Lee MC, Choi CW, Yau TK, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys. 2009;73(5):1335-42.

Cheraghi S, Nikoofar P, Fadavi P, Bakhshandeh M. Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy. Med Oncol. 2015:1–7.

Zuur CL, Smis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, et al. Risk factors of ototoxicity after cisplatin-based chemo- irradiation in patients with locally advanced head-and- neck cancer : a multivariate analysis. Int J Radiat Oncol Biol Phys. 2007;68(5):1320–5.